NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the Bundibugyo Ebolavirus (BDBV) outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is progressing as planned, with enrollment in Phase IIA set to begin on or about September 23, 2026. This milestone is significant because it marks the first clinical evaluation of an oral antiviral candidate specifically designed to combat Ebola, a disease that has historically required intravenous therapies administered in specialized healthcare settings.
Phase IIA is designed to identify an optimal, well-tolerated dosing regimen and will serve as a go/no-go decision point before Phase IIB, a randomized controlled trial that will evaluate efficacy. NV-387 is a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses to enter cells, thereby attacking the virus and reducing viral load. Delivered as an oral gummy that dissolves in the mouth without the need for water or swallowing, the treatment could be readily deployed in resource-limited settings where outbreaks often occur. This ease of administration is a critical advantage, as it could enable faster and more widespread distribution during outbreaks, potentially saving lives by reducing the logistical barriers associated with injectable drugs.
The implications of this trial extend beyond Ebola. NanoViricides’ platform technology, which is based on TheraCour Pharma’s nanomedicine technology, has the potential to be applied to a range of viral diseases. The company is also developing drugs against oral and genital herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and other Ebola viruses. If successful, NV-387 could represent a new class of broad-spectrum antivirals that are easy to administer and highly effective, addressing a significant unmet need in global health.
For investors, the progression of NV-387 into Phase II is a key catalyst. The company’s lead drug candidate is being developed as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The outcome of the Ebola trial could provide valuable data on the safety and efficacy of the platform, potentially accelerating development for other indications. However, as with any drug development, there are risks, and the company notes that there can be no assurance that any candidate will show sufficient effectiveness and safety for human clinical development.
To view the full press release, visit https://ibn.fm/zjg8X. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. For more information about NanoViricides, visit www.nanoviricides.com. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
